AA
AGN

Antipodean Advisors’s Allergan plc AGN Stock Holding History

Antipodean Advisors’s Portfolio AGN Stock Details AGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-207,000
Closed -$64.7M – 23
2015
Q4 		$64.7M Buy
+207,000
New +$61.6M 9.44% 5
2013
Q4 		– Sell
-71,000
Closed -$10.2M – 36
2013
Q3 		$10.2M Buy
+71,000
New +$9.46M 1.07% 24

Other funds holding AGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Antipodean Advisors's AGN Position: Q1 2016 in Review

Antipodean Advisors sold out of Allergan plc (AGN) in Q1 2016, closing a stake of 207,000 shares — an estimated $64.7M sold.

Antipodean Advisors first reported a position in AGN in Q3 2013 and held it in 2 quarters. The position peaked at $64.7M in Q4 2015. 1,119 funds tracked by Wall St. Rank hold AGN as of Q1 2016.

  • Antipodean Advisors reported no remaining Allergan plc position as of Q1 2016 after selling out during the quarter.
  • Antipodean Advisors sold 207,000 Allergan plc shares in Q1 2016, an estimated $64.7M.
  • Antipodean Advisors first reported a position in Allergan plc in Q3 2013 and held it in 2 quarters.
  • Antipodean Advisors's Allergan plc position peaked at $64.7M in Q4 2015.
  • 1,119 funds tracked by Wall St. Rank held Allergan plc as of Q1 2016.

Based on Antipodean Advisors's 13F filing for Q1 2016, filed 16 May 2016.